A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures

被引:38
作者
Lee, Yi-Chia
Wu, Hui-Min
Chen, Tony Hsiu-Hsi
Liu, Tzeng-Ying
Chiu, Han-Mo
Chang, Chun-Chao
Wang, Hsiu-Po
Wu, Ming-Shiang
Chiang, Hung
Wu, Meng-Chen
Lin, Jaw-Town
机构
[1] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[2] Natl Taiwan Univ, Coll Publ Hlth, Inst Prevent Med, Taipei 10764, Taiwan
[3] Hlth Bur Lienchiang Cty, Matsu, Taiwan
[4] Taipei Med Univ Hosp, Dept Internal Med, Taipei, Taiwan
[5] Natl Taiwan Univ, Coll Med, Dept Emergency Med, Taipei 10764, Taiwan
[6] Taipei Inst Pathol, Taipei, Taiwan
关键词
antibiotic regimen; gastric cancer; Helicobacter pylori; population-based study;
D O I
10.1111/j.1523-5378.2006.00432.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Although eradication of Helicobacter pylori infection can decrease the risk of gastric cancer, the optimal regimen for treating the general population remains unclear. We report the eradication rate (intention-to-treat and per protocol) of a community-based H. pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Materials and methods: In 2004, a total of 2658 residents were recruited for C-13-urea breath testing. Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily), and a 10-day re-treatment (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and levofloxacin 500 mg once daily) if the follow-up tests remained positive. Both H. pylori status and side-effects were assessed 6 weeks after treatment. Results: Among 886 valid reporters, eradication rates with initial therapy were 86.9% (95% confidence interval [CI]: 84.7-89.1%) and 88.7% (95%CI: 86.5-90.9%) by intention-to-treat and per protocol analysis, respectively. Re-treatment eradicated infection in 91.4% (95%CI: 86-96.8%) of 105 nonresponders. Adequate compliance was achieved in 798 (90.1%) of 886 subjects receiving the initial treatment and in all 105 re-treated subjects. Mild side-effects occurred in 24% of subjects. Overall intention-to-treat and per protocol eradication rates were 97.7% (95%CI: 96.7-98.7%) and 98.8% (95%CI: 98.5-99.3%), respectively, which were only affected by poor compliance (odds ratio, 3.3; 95%CI, 1.99-5.48; p < .0001). Conclusions: A comprehensive plan using drugs in which the resistance rate is low in a population combined with the strategy of test, treat, retest, and re-treat of needed can result in virtual eradication of H. pylori from a population. This provides a model for planning country- or region-wide eradication programs.
引用
收藏
页码:418 / 424
页数:7
相关论文
共 33 条
[1]   A 10-Day Levofloxacin-Based Therapy in Patients With Resistant Helicobacter pylori Infection: A Controlled Trial [J].
Bilardi, Claudio ;
Dulbecco, Pietro ;
Zentilin, Patrizia ;
Reglioni, Simona ;
Iiritano, Elena ;
Parodi, Andrea ;
Accornero, Laura ;
Savarino, Edoardo ;
Mansi, Carlo ;
Mamone, Mario ;
Vigneri, Sergio ;
Savarino, Vincenzo .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) :997-1002
[2]   Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication:: 7 vs. 14 day treatment [J].
Bosques-Padilla, FJ ;
Garza-González, E ;
Calderón-Lozano, IE ;
Reed-SanRoman, G ;
de Ariño Suárez, M ;
Valdovinos-Díaz, MA ;
Orozco-Gámiz, A ;
Blancas-Valencia, JM ;
Tamayo-de la Cuesta, JL .
HELICOBACTER, 2004, 9 (05) :417-421
[3]   Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection [J].
Cammarota, G ;
Cianci, R ;
Cannizzaro, O ;
Cuoco, L ;
Pirozzi, G ;
Gasbarrini, A ;
Armuzzi, A ;
Zocco, MA ;
Santarelli, L ;
Arancio, F ;
Gasbarrini, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1339-1343
[4]   Community-based multiple screening model - Design, implementation, and analysis of 42,387 participants Taiwan community-based integrated screening group [J].
Chen, THH ;
Chiu, YH ;
Luh, DL ;
Yen, MF ;
Wu, HM ;
Chen, LS ;
Tung, TH ;
Huang, CC ;
Chan, CC ;
Shiu, MN ;
Yeh, YP ;
Liou, HH ;
Liao, CS ;
Lai, HC ;
Chiang, CP ;
Peng, HL ;
Tseng, CD ;
Yen, MS ;
Hsu, WC ;
Chen, CH .
CANCER, 2004, 100 (08) :1734-1743
[5]   Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection [J].
Chen, TS ;
Chang, FY ;
Chen, PC ;
Huang, TW ;
Ou, JT ;
Tsai, MH ;
Wu, MS ;
Lin, JT .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (11) :1237-1243
[6]   Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori [J].
Chi, CH ;
Lin, CY ;
Sheu, BS ;
Yang, HB ;
Huang, AH ;
Wu, JJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (03) :347-353
[7]  
CORREA P, 1992, CANCER RES, V52, P6735
[8]   Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia [J].
De Francesco, V ;
Della Valle, N ;
Stoppino, V ;
Amoruso, A ;
Muscatiello, N ;
Panella, C ;
Ierardi, E .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (09) :993-998
[9]  
*DEP HLTH, 2004, MAIN CAUS DEATH CANC
[10]   Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori:: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer [J].
Ducóns, JA ;
Santolaria, S ;
Guirao, R ;
Ferrero, M ;
Montoro, M ;
Gomollón, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) :775-780